{
  "source": "PA-Notification-Fabhalta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1432-4\nProgram Prior Authorization/Notification\nMedication Fabhalta® (iptacopan)\nP&T Approval Date 2/2024, 4/2024, 10/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nFabhalta (iptacopan) a complement factor B inhibitor, indicated for the treatment of adults with\nparoxysmal nocturnal hemoglobinuria (PNH), the reduction of proteinuria in adults with primary\nimmunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine\nprotein-to-creatinine ratio (UPCR) ≥1.5 g/g, and for the treatment of adults with complement 3\nglomerulopathy (C3G), to reduce proteinuria.\n2. Coverage Criteriaa:\nA. Paroxysmal nocturnal hemoglobinuria (PNH)\n1. Initial Authorization\na. Fabhalta will be approved based on both of the following criteria:\n(1) Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)\n-AND-\n(2) One of the following:\n(a) Patient will not be prescribed Fabhalta in combination with another\ncomplement inhibitor used for the treatment of PNH (e.g., eculizumab,\nEmpaveli, PiaSky, Ultomiris)\n-OR-\n(b) Patient is currently receiving another complement inhibitor (e.g.,\neculizumab, Empaveli, PiaSky, Ultomiris) which will be discontinued and\nFabhalta will be initiated in accordance with the United States Food and\nDrug Administration approved labeling\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Fabhalta will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Fabhalta therapy\n© 2025 UnitedHealthcare Services Inc.\n1\n-AND-\n(2) Patient is not receiving Fabhalta in combination with another complement\ninhibitor used for the treatment of PNH (e.g., eculizumab, Empaveli, PiaSky,\nUltomiris)\nAuthorization will be issued for 12 months.\nB. Primary immunoglobulin A nephropathy (IgAN)\n1. Initial Authorization\na. Fabhalta will be approved based on all the following criteria:\n(1) Diagnosis of primary immunoglobulin A nephropathy",
    " months.\nB. Primary immunoglobulin A nephropathy (IgAN)\n1. Initial Authorization\na. Fabhalta will be approved based on all the following criteria:\n(1) Diagnosis of primary immunoglobulin A nephropathy (IgAN)\n-AND-\n(2) Patient is at risk of rapid disease progression [e.g., generally a urine protein-to-\ncreatinine ratio (UPCR) greater than or equal to 1.5 g/g]\n-AND-\n(3) Used to reduce proteinuria\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Fabhalta will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Fabhalta therapy\nAuthorization will be issued for 12 months.\nC. Complement 3 glomerulopathy (C3G)\n1. Initial Authorization\na. Fabhalta will be approved based on both the following criteria:\n(1) Diagnosis of complement 3 glomerulopathy (C3G)\n-AND-\n(2) Used to reduce proteinuria\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services Inc.\n2\na. Fabhalta will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Fabhalta therapy demonstrated\nby a reduction in proteinuria\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may also be in place.\n4. References:\n1. Fabhalta [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation;\nMarch 2025.\nProgram Prior Authorization/Notification - Fabhalta® (iptacopan)\nChange Control\n2/2024 New program\n4/2024 Simplified criteria language for co",
    " Jersey: Novartis Pharmaceuticals Corporation;\nMarch 2025.\nProgram Prior Authorization/Notification - Fabhalta® (iptacopan)\nChange Control\n2/2024 New program\n4/2024 Simplified criteria language for converting to new complement inhibitor\ntherapy.\n10/2024 Updated background and added coverage criteria with additional\nindication for primary immunoglobulin A nephropathy (IgAN).\nUpdated list of examples for combination use requirement for PNH.\nUpdated reference.\n5/2025 Added new indication and criteria for C3 glomerulopathy (C3G).\nReplaced Soliris with eculizumab in list of examples of complement\ninhibitors. Updated background and references.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}